Editorial: Prerequisites for a Successful Probiotic Therapy in Dysbiosis

This article briefly addresses why many forms of probiotic treatment are unsound and provides a set of prerequisites to increase the effectiveness of improved probiotic delivery. We pay particular attention to why probiotics largely fail, then suggest prerequisite principles that favor successful long-term engraftment.

Ethical Statement

Not applicable.

Author Contributions

All authors contributed equally to the article.

Data Availability Statement

There is no data associated with this work.

Publikationsverlauf

Eingereicht: 17. Oktober 2022

Angenommen: 19. Oktober 2022

Artikel online veröffentlicht:
22. September 2023

• References

• 1 Zmora N, Zilberman-Schapira G, Suez J. et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell 2018; 174 (06) 1388-1405.e21
• 2 McFarland LV. Probiotics for the primary and secondary prevention of C. difficile infections: a meta-analysis and systematic review. Antibiotics (Basel) 2015; 4 (02) 160-178
• 3 Allen SJ, Wareham K, Wang D. et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2013; 382 (9900): 1249-1257
• 4 Goldenberg JZ, Yap C, Lytvyn L. et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2017; 12 (12) CD006095
• 5 Shogbesan O, Poudel DR, Victor S. et al. A systematic review of the efficacy and safety of fecal microbiota transplant for Clostridium difficile infection in immunocompromised patients. Can J Gastroenterol Hepatol 2018; 2018: 1394379
• 6 Quraishi MN, Widlak M, Bhala N. et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther 2017; 46 (05) 479-493
• 7 Kristensen NB, Bryrup T, Allin KH, Nielsen T, Hansen TH, Pedersen O. Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials. Genome Med 2016; 8 (01) 52
• 8 Smillie CS, Sauk J, Gevers D. et al. Strain-tracking reveals the determinants of bacterial engraftment in the human gut following fecal microbiota transplantation. Cell Host Microbe 2018; 23 (02) 229-240.e5
• 9 Kapourchali FR, Cresci GAM. Early-life gut microbiome-the importance of maternal and infant factors in its establishment. Nutr Clin Pract 2020; 35 (03) 386-405
• 10 Kong L, Lloyd-Price J, Vatanen T. et al. Linking strain engraftment in fecal microbiota transplantation with maintenance of remission in Crohn's disease. Gastroenterology 2020; 159 (06) 2193-2202.e5
• 11 Bajaj JS, Kassam Z, Fagan A. et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology 2017; 66 (06) 1727-1738
• 12 Cammarota G, Ianiro G, Tilg H. et al; European FMT Working Group. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017; 66 (04) 569-580
• 13 Wilson BC, Vatanen T, Cutfield WS, O'Sullivan JM. The super-donor phenomenon in fecal microbiota transplantation. Front Cell Infect Microbiol 2019; 9: 2
• 14 Vermeire S, Joossens M, Verbeke K. et al. Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J Crohn's Colitis 2016; 10 (04) 387-394
• 15 Han C, Song J, Hu J. et al. Smectite promotes probiotic biofilm formation in the gut for cancer immunotherapy. Cell Rep 2021; 34 (06) 108706
• 16 Tariq R. Systematic review and meta-analysis: safety and efficacy of Saccharomyces boulardii for prevention of Clostridioides difficile infection. J Gastrointest Infect 2022; 12 (02) 94-100